{"denoms":[{"counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"46"}],"units":"Participants"}],"groups":[{"description":"Clofarabine/Busulfan x 4 : Clofarabine IV 20 mg/m\\^2/day x 5 days\n\nBusulfan IV 3.2 mg/kg daily x 4 days\n\nPeripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.","id":"BG000","title":"Clo/BU4 20mg/m^2"},{"description":"Clofarabine/Busulfan x 4 : Clofarabine IV 30 mg/m\\^2/day x 5 days\n\nBusulfan IV 3.2 mg/kg daily x 4 days\n\nPeripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.","id":"BG001","title":"Clo/BU4 30mg/m^2"},{"description":"Clofarabine/Busulfan x 4 : Clofarabine IV 40 mg/m\\^2/day x 5 days\n\nBusulfan IV 3.2 mg/kg daily x 4 days\n\nPeripheral blood stem cell transplant : Peripheral blood stem cell transplant, after pre-conditioning drug treatment.","id":"BG002","title":"Clo/BU4 40mg/m^2"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"14","upperLimit":"61","value":"48.5"},{"groupId":"BG001","lowerLimit":"18","upperLimit":"68","value":"54"},{"groupId":"BG002","lowerLimit":"1","upperLimit":"67","value":"51"},{"groupId":"BG003","lowerLimit":"1","upperLimit":"68","value":"53"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"22"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"24"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"46"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"31"}]}],"title":"Acute Myeloid Leukemia (AML)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}],"title":"Chronic Myeloid Leukemia (CML)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"}]}],"title":"Acute Lymphoblastic Leukemia (ALL)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}]}],"title":"Chronic Lymphocytic Leukemia (CLL)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]}],"title":"Non-Hodgkin Lymphoma (NHL)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]}],"title":"Myelodysplastic Syndromes (MDS)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}],"title":"Multiple Myeloma (MM)"}],"description":"The number of patients with each disease type.","paramType":"NUMBER","title":"Disease","unitOfMeasure":"participants"}],"populationDescription":"Experimental: Clo/BU4"}